Ocular Therapeutix Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

San Diego, California--(Newsfile Corp. - February 19, 2026) - Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Ocular Therapeutix, Inc. (NASDAQ: OCUL). The investigation focuses on Ocular's executive officers and whether investor losses may be recovered under federal securities laws.

Newsfile Corp • Feb 19, 2026

Ocular Therapeutix's eye drug superior to Regeneron's Eylea in late-stage trial

Ocular Therapeutix said on Tuesday its experimental eye disease drug was more effective in helping patients maintain their vision compared to Regeneron's approved treatment Eylea in a late-stage trial.

Reuters • Feb 17, 2026

Ocular Therapeutix, Inc. (OCUL) Discusses Positive Top Line Results From SOL-1 Phase 3 Trial of AXPAXLI in Wet AMD Transcript

Ocular Therapeutix, Inc. (OCUL) Discusses Positive Top Line Results From SOL-1 Phase 3 Trial of AXPAXLI in Wet AMD Transcript

Seeking Alpha • Feb 17, 2026

Ocular Therapeutix™ to Announce Topline Data for SOL-1 Phase 3 Superiority Trial in Wet AMD on Tuesday, February 17, 2026

Ocular to host webcast scheduled for Tuesday, February 17, 2026, at 8:00 AM ET Detailed SOL-1 data to be presented at the 49 th Macula Society Annual Meeting BEDFORD, Mass., Feb. 13, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that the Company will host a webcast to review the topline results of the SOL-1 Phase 3 superiority clinical trial of AXPAXLI™ (also known as OTX-TKI), for the treatment of wet age-related macular degeneration (wet AMD), on Tuesday, February 17, 2026.

GlobeNewsWire • Feb 13, 2026

Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

BEDFORD, Mass., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducement awards to five newly hired non-executive employees. The awards were made as an inducement material to each recipient's acceptance of employment with Ocular under Ocular's 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

GlobeNewsWire • Feb 6, 2026

Ocular Therapeutix (OCUL) Reports Q4 Loss, Misses Revenue Estimates

Ocular Therapeutix (OCUL) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to a loss of $0.29 per share a year ago.

Zacks Investment Research • Feb 5, 2026

Ocular Therapeutix: Why SOL-1 Trial Outcome Is Likely Positive

Ocular Therapeutix (OCUL) is a Strong Buy, driven by the pivotal SOL-1 Phase 3 trial for AXPAXLI™ in wet AMD, with topline results expected Q1 2026. AXPAXLI™ leverages proven science and a de-risked trial design, aiming to reduce injection frequency while maintaining vision, targeting a $10B+ market. Phase 1 data and masked SOL-1 observations suggest a high probability of meeting key endpoints, with minimal safety concerns to date.

Seeking Alpha • Feb 4, 2026

Ocular Therapeutix Launches On Rumors Sanofi Is Preparing A Bigger Bid

Shares of Ocular Therapeutix launched Thursday on reports Sanofi is preparing an improved bid to buy it.

Investors Business Daily • Jan 15, 2026

Strength Seen in Ocular Therapeutix (OCUL): Can Its 6.1% Jump Turn into More Strength?

Ocular Therapeutix (OCUL) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks Investment Research • Jan 15, 2026

Biotech outperformance expected to continue in 2026, Baird analysts say

The biotechnology sector's strong fundamentals and robust innovation could continue to drive outperformance this year, according to Baird analysts. The firm noted that while macroeconomic risks such as rising interest rates remain, the biotechnology sector's underlying drivers are supportive.

Proactive Investors • Jan 9, 2026